<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04828343</url>
  </required_header>
  <id_info>
    <org_study_id>UP0106</org_study_id>
    <secondary_id>2020-005973-28</secondary_id>
    <nct_id>NCT04828343</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants</brief_title>
  <official_title>A Randomized, Participant-Blind, Investigator-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma SRL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and&#xD;
      pharmacodynamics (PD) of a single subcutaneous (SC) dose of rozanolixizumab administered to&#xD;
      healthy participants by manual push (MP) versus (vs) syringe driver.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This is a participant-blind and investigator-blind study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>From start of dosing (Day 1) to End of Safety Follow-Up (up to Day 57)</time_frame>
    <description>A TEAE is defined as any adverse event (AE) with a start date/time on or after the dosing of study medication until 8 weeks after dosing of study medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of a single dose rozanolixizumab</measure>
    <time_frame>Sampling time points for plasma Pharmacokinetics will be as follows: predose, immediately at the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, and 16</time_frame>
    <description>Cmax: Maximum plasma concentration of a single dose rozanolixizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (tmax) of a single dose rozanolixizumab</measure>
    <time_frame>Sampling time points for plasma Pharmacokinetics will be as follows: predose, immediately at the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, and 16</time_frame>
    <description>tmax: Time to maximum plasma concentration of a single dose rozanolixizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to time t (AUC0-t) of a single dose rozanolixizumab</measure>
    <time_frame>Sampling time points for plasma Pharmacokinetics will be as follows: predose, immediately at the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, and 16</time_frame>
    <description>AUC0-t: Area under the plasma concentration-time curve from time zero to time t of a single dose rozanolixizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline-corrected area under the Total immunglobulin (Ig) G-time curve</measure>
    <time_frame>Sampling time points for total IgG will be as follows: 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, 16, 19, 22, 29, 43 and 57</time_frame>
    <description>Area under the baseline-corrected total IgG response curve from time 0 to time t</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum decrease in total plasma IgG (Rmin) of a single dose rozanolixizumab</measure>
    <time_frame>Sampling time points for total IgG will be as follows: 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, 16, 19, 22, 29, 43 and 57</time_frame>
    <description>Rmin: Maximum decrease in total plasma IgG of a single dose rozanolixizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to minimum IgG level (tmin) of a single dose rozanolixizumab</measure>
    <time_frame>Sampling time points for total IgG will be as follows: 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, 16, 19, 22, 29, 43 and 57</time_frame>
    <description>tmin: Time to minimum IgG level of a single dose rozanolixizumab</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy Study Participants</condition>
  <arm_group>
    <arm_group_label>Cohort 1 &lt;50 kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants randomized to Cohort 1 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered with a syringe driver.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 &lt;50 kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants randomized to Cohort 2 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered by manual push.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 &gt;=50 kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants randomized to Cohort 3 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered with a syringe driver.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 &gt;=50 kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants randomized to Cohort 4 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered by manual push.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rozanolixizumab</intervention_name>
    <description>Study participants will receive a single dose rozanolixizumab subcutaneously administered by manual push or a syringe driver.</description>
    <arm_group_label>Cohort 1 &lt;50 kg</arm_group_label>
    <arm_group_label>Cohort 2 &lt;50 kg</arm_group_label>
    <arm_group_label>Cohort 3 &gt;=50 kg</arm_group_label>
    <arm_group_label>Cohort 4 &gt;=50 kg</arm_group_label>
    <other_name>RLZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Study participants will receive a single dose placebo subcutaneously administered by manual push or a syringe driver.</description>
    <arm_group_label>Cohort 1 &lt;50 kg</arm_group_label>
    <arm_group_label>Cohort 2 &lt;50 kg</arm_group_label>
    <arm_group_label>Cohort 3 &gt;=50 kg</arm_group_label>
    <arm_group_label>Cohort 4 &gt;=50 kg</arm_group_label>
    <other_name>PBO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Study participant must be 18 to 65 years of age, inclusive&#xD;
&#xD;
          -  Study participants who are overtly healthy in the opinion of the investigator as&#xD;
             determined by medical evaluation including medical history, a general clinical&#xD;
             examination, including physical examination and laboratory tests, and cardiac&#xD;
             monitoring&#xD;
&#xD;
          -  Study participant has blood pressure (BP) and pulse within normal range in a supine&#xD;
             position after 5 minutes of rest (systolic BP: 90 to 140 mmHg, diastolic BP: 50 to 90&#xD;
             mmHg, pulse: 40 to 90 beats per minute (bpm))&#xD;
&#xD;
          -  Study participant has clinical laboratory test results within the reference ranges of&#xD;
             the testing laboratory or not clinically significant if outside the specified ranges,&#xD;
             in the opinion of the investigator&#xD;
&#xD;
          -  Study participant's electrocardiogram (ECG) is considered &quot;normal&quot; or &quot;abnormal but&#xD;
             clinically nonsignificant&quot; (as interpreted by the investigator)&#xD;
&#xD;
          -  Study participants may be male or female&#xD;
&#xD;
          -  Participant has a body mass index of 18 to 32 kg/m^2, with a minimum body weight of 35&#xD;
             kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of/significant history of or current cardiovascular, respiratory,&#xD;
             hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological&#xD;
             disorders. Has active neoplastic disease or history of neoplastic disease within the&#xD;
             previous 5 years of entry in the clinical study (except for basal or squamous cell&#xD;
             carcinoma of the skin or carcinoma in situ that has been definitively treated with&#xD;
             standard of care approaches). Has a history of a major organ transplant or&#xD;
             hematopoietic stem cell/marrow transplant&#xD;
&#xD;
          -  Symptomatic herpes zoster within 3 months prior to Screening&#xD;
&#xD;
          -  Allergies to humanized monoclonal antibodies&#xD;
&#xD;
          -  Female who is pregnant or lactating&#xD;
&#xD;
          -  Clinically significant multiple or severe drug allergies, intolerance to topical&#xD;
             corticosteroids, or severe posttreatment hypersensitivity reactions&#xD;
&#xD;
          -  Evidence of active or latent tuberculosis (TB) as documented by medical history and&#xD;
             examination&#xD;
&#xD;
          -  Predicted inability to comply with being free of caffeine and ethanol from 72 hours&#xD;
             prior to clinic admission and during the In-Clinic Period of the study&#xD;
&#xD;
          -  Known hypersensitivity to oral paracetamol (acetaminophen)&#xD;
&#xD;
          -  History of known inflammatory bowel disease, active diverticular disease, or a history&#xD;
             of confirmed duodenal, gastric, or esophageal ulceration in the previous 6 months&#xD;
&#xD;
          -  History of hyperprolinemia, since L-proline is a constituent of rozanolixizumab.&#xD;
&#xD;
          -  Twelve-lead ECG with abnormalities considered to be clinically significant upon&#xD;
             medical review&#xD;
&#xD;
          -  Renal impairment, defined as a creatinine concentration in serum of ≥1.4 mg/dL (≥123&#xD;
             μmol/L) for female participants and ≥1.5 mg/dL (≥132 μmol/L) for male participants&#xD;
&#xD;
          -  Known viral hepatitis (B and C) or human immunodeficiency virus 1/2 antibodies or has&#xD;
             a past medical history or family history of primary immunodeficiency or antibodies to&#xD;
             human immunodeficiency virus type 1 and/or type 2 at Screening&#xD;
&#xD;
          -  Participant has a positive test result for severe acute respiratory syndrome&#xD;
             coronavirus 2 (SARS-CoV-2) in reverse transcriptase-polymerase chain reaction on&#xD;
             admission to the unit&#xD;
&#xD;
          -  Participant has clinical signs and symptoms consistent with SARS-CoV-2 (eg, fever, dry&#xD;
             cough, dyspnea, sore throat, fatigue) or confirmed infection by appropriate laboratory&#xD;
             test within the previous 14 days prior to Screening or on admission&#xD;
&#xD;
          -  Participant has active infection or is symptomatic with SARS-CoV-2 or is currently in&#xD;
             quarantine (has been in contact with a SARS-CoV-2 positive individual in the last 14&#xD;
             days)&#xD;
&#xD;
          -  Participant has had a severe course of SARS-CoV-2 (eg, requiring extracorporeal&#xD;
             membrane oxygenation, mechanical ventilation, or hospitalization)&#xD;
&#xD;
          -  Past or intended use of over-the-counter or prescription medication (including herbal&#xD;
             medications) within 14 days prior to dosing until Day 57&#xD;
&#xD;
          -  Live vaccine(s) within 8 weeks prior to Screening or plans to receive such vaccines&#xD;
             during the study or is within a dosing cycle to receive a second dose of a coronavirus&#xD;
             disease-19 (COVID-19) vaccine, or within 2 weeks of having received a COVID-19 vaccine&#xD;
&#xD;
          -  Treatment with biologic agents (such as monoclonal antibodies including marketed&#xD;
             drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing&#xD;
&#xD;
          -  Exposure to more than 3 new chemical entities within 12 months prior to dosing&#xD;
&#xD;
          -  Has previously been assigned to treatment in a clinical study of rozanolixizumab&#xD;
&#xD;
          -  Participated in another study of an investigational medicinal product (IMP) (or a&#xD;
             medical device) within the previous 90 days or 5 half-lives prior to Day -1 (whichever&#xD;
             is longer) or is currently participating in another study of an IMP (or a medical&#xD;
             device)&#xD;
&#xD;
          -  Immunoglobulin G &lt;7g/L or &gt;16g/L at the Screening Visit&#xD;
&#xD;
          -  Participant is splenectomized or has had an active clinically significant infection&#xD;
             within the last 6 weeks&#xD;
&#xD;
          -  Donated or lost &gt;500 mL of blood or blood products in the 3 months preceding the start&#xD;
             of dosing or plans to donate blood during the clinical study&#xD;
&#xD;
          -  Employee or direct relative of an employee of the contract research organization (CRO)&#xD;
             or UCB&#xD;
&#xD;
          -  History of alcohol and/or drug abuse up to 12 months before Screening&#xD;
&#xD;
          -  Smoked on average &gt;5 cigarettes/day (or equivalent) during the last 3 months and is&#xD;
             not able to stop smoking during the In-Clinic Period&#xD;
&#xD;
          -  Excessive consumption of beverages or food containing xanthine bases (including&#xD;
             caffeinated drinks, coffee, chocolate, etc.), equating to &gt;400 mg caffeine per day&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>001 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UCB Cares</last_name>
    <phone>+1844599</phone>
    <phone_ext>2273</phone_ext>
    <email>UCBCares@ucb.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Up0106 001</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Study Participants</keyword>
  <keyword>Phase 1</keyword>
  <keyword>rozanolixizumab</keyword>
  <keyword>manual push</keyword>
  <keyword>syringe driver</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rozanolixizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Due to the small sample size in this trial, IPD cannot be adequately anonymized i.e., there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

